TheraVasc
-
TheraVasc’s clinical trial of PAD drug shows safety in diabetic patients
A phase 1 trial of a peripheral artery disease drug candidate from TheraVasc demonstrated safety […]
-
Peripheral artery disease pill from TheraVasc heading to phase 2a trials
TheraVasc plans to begin enrolling patients this month in a phase 2a clinical trial of […]
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Peripheral artery disease drug developer TheraVasc raises $1.8M
TheraVasc Inc., which is reformulating a drug to treat vascular diseases, has raised a $1.8 million Series A1 round of investment capital. But the company isn’t stopping there — it’s looking to add about $450,000 to the round.
-
Max Endoscopy, TheraVasc get 250k investments from JumpStart
Device maker MAX Endoscopy Inc. and drug developer TheraVasc Inc. each have received $250,000 follow-on investments from JumpStart Ventures, the investment arm of Northeast Ohio venture developer JumpStart Inc. The new commitments follow initial investments of the same amount that JumpStart made in the two companies last winter.
-
Theravasc Inc. wins $500,000 investment commitment to try vascular disease drug
Theravasc Inc., a Cleveland company that is reformulating an approved drug to treat vascular diseases, has received investment commitments of $500,000 to do its initial clinical study.
-
Louisiana pharma startup TheraVasc moves, readies for clinical trials
TheraVasc, based in Shreveport, Louisiana, wants to raise $2.5 million in a Series A round, said President Tony Giordano. It would close on most of the money by the fall and launch a Phase Ib clinical trial to test how its drug, TV1001i, works to restore blood vessels damaged through peripheral artery disease.